购物车
您的购物车当前为空
Olendalizumab (ALXN1007)为源自小鼠的人源化IgG2-G4-κ抗体,专一靶向补体蛋白C5a(Ki=60 pM),用于探究冠状病毒引发的补体介导疾病,并针对补体炎症通路。
Olendalizumab (ALXN1007)为源自小鼠的人源化IgG2-G4-κ抗体,专一靶向补体蛋白C5a(Ki=60 pM),用于探究冠状病毒引发的补体介导疾病,并针对补体炎症通路。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5 mg | 待询 | 待询 |
| 产品描述 | Olendalizumab (ALXN1007), a humanized IgG2-G4-κ antibody derived from mice, specifically targets Complement protein C5a with a binding affinity (K i) of 60 pM. This compound is designed to inhibit the complement inflammatory pathway. Additionally, olendalizumab is utilized in the research of complement-mediated disorders triggered by the coronavirus [1] [2]. |
| 反应种属 | Virus |
| 应用 | ELISA FACS Functional assay |
| 抗体种类 | Monoclonal |
| 内毒素 | < 1.0 EU/mg |
| 同型 | IgG2SA |
| 偶联 | Unconjugated |
| Uniprot ID | |
| 靶点 | ComplementproteinC5a |
| CAS No. | 2210314-30-8 |
| 存储 | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
对于不同动物的给药剂量换算,您也可以参考 更多